Shares of Ranbaxy Laboratories and Sun Pharma saw buying interest today, rising by up to 3.5 per cent, as the US Federal Trade Commission (FTC) completed its review of the proposed $4-billion acquisition of Ranbaxy by Sun Pharma.
Stocks of Ranbaxy climbed 3.46 per cent to Rs 728 — its one-year peak on the BSE. Sun Pharma rose 2.84 per cent to touch its 52-week high of Rs 942.
“The US Federal Trade Commission (FTC) has completed its review of the proposed acquisition of Ranbaxy by Sun Pharma and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act),” Sun Pharmaceutical Industries and Ranbaxy Laboratories said in a joint statement.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.